Legend Biotech Releases Debut Environmental, Social, and Governance (ESG) Report
Legend Biotech Corporation (NASDAQ: LEGN), a leading global figure in cell therapy, has unveiled its inaugural Environmental, Social & Governance (ESG) report. This comprehensive document provides an insight into Legend…
Viatris Announces Closure of Global Research and Development Collaboration with Idorsia: Official Statement
Viatris Inc. recently concluded agreements for a comprehensive global research and development collaboration with Idorsia Ltd (SIX: IDIA), a transaction that was finalized on March 15, 2024. For detailed information…
WuXi Biologics Commences Construction on CRDMO Facility in Singapore
WuXi Biologics announced a USD$1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO center will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions…
Labcorp Introduces pTau217 Blood Test for Faster Alzheimer’s Diagnosis and Clinical Trial Support
Labcorp, a leading provider of cutting-edge laboratory services, has unveiled its latest breakthrough: a test capable of detecting phosphorylated tau 217 (pTau217) in the blood. This innovative biomarker serves as…
Dating a Person in Her 50s
A woman in her 50’s has frequently had enough knowledge in relationships to know what she wants and is n’t willing to settle. She is usually done making the same…
Pfizer Reports Encouraging Overall Survival Results in Phase 3 Study of ADCETRIS® Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Pfizer Inc. (NYSE: PFE) has disclosed promising findings from a Phase 3 clinical trial investigating the efficacy of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in conjunction with lenalidomide and rituximab…
Roche Annual General Meeting 2024
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the successful approval of all proposed resolutions by its shareholders at the Annual General Meeting. The meeting saw 77.02% of the total…
KEYTRUDA® Boosts Survival in High-Risk Locally Advanced Cervical Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has announced the successful outcome of the Phase 3 KEYNOTE-A18 trial, also recognized as ENGOT-cx11 This trial…
Merck Unveils Clinical Trial Strategy for New HPV Vaccine and GARDASIL®9 Single-Dose Regimen
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, made a significant announcement today at the EUROGIN 2024 HPV Congress. The company revealed its intentions to…
Hansoh Pharma Enhances Collaboration with Biotheus to Advance Development of EGFR/cMET Bispecific Antibody-Drug Conjugates
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovative pharmaceutical company in China, and Biotheus Inc. (Biotheus), a clinical-stage biotech company specializing in biologics for oncology and inflammatory…
Update Consultation by WHO Experts: Revising Toxic Equivalency Factors for Dioxin-like Compounds and Selected Polychlorinated Biphenyls
In Lisbon, Portugal, the World Health Organization (WHO) recently hosted an expert panel to reassess the Toxic Equivalency Factors (TEFs) for chlorinated dioxin-like compounds, initially established in 2005. Background: Since…
Neurological Conditions Impact Over 1 in 3 Individuals, Ranking as the Primary Cause of Global Illness and Disability
A recent comprehensive study, published in The Lancet Neurology, has revealed staggering figures regarding neurological conditions worldwide. In 2021, over 3 billion individuals were found to be living with such…